Ucb S.a. · EURONEXT:UCB
Ucb — FY2023 Earnings Presentation
22 slides from Ucb's earnings presentation, Feb 28, 2024
Slide 1: FY 2023 Results: UCB on Growth Path for a Decade+
FY 2023 Results UCB on Growth Path for a Decade+ Our Purpose: Create value for patients, now and into the future Capital Market Earnings Call 28 February 2024
Slide 2: Disclaimer & Safe harbor
Disclaimer & Safe harbor This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-loo
Slide 3: Agenda
Agenda 01 02 03 04 05 Proprietary and Confidential Property of UCB Leading BIMZELX® offering Promising Strong financial Solid foundation & innovation driving potential for best pipeline management differentiated UCB’s growth in disease and complementing the through growth innovation best in class ex
Slide 4: Introduction: Leading Innovation Driving UCB's Growth
01 Introduction Proprietary and Confidential Property of UCB Leading Innovation Driving UCB’s Growth Jean-Christophe Tellier CEO UCB - FY results 2023, February 2024 4
Slide 5: UCB's Achievements – Innovation
UCB’s Achievements – Innovation Impressive Successes to date, based on Innovation, enabling Company Growth UCB's innovative spirit is exemplified by an impressive 2023 FDA Approvals for Major Pharma1 tally of 10 + 2 positive phase 3 readouts 5 2nd most internally developed NME - 4 FDA approvals Exte
Slide 6: UCB's Portfolio Unique and De-risked Growth Drivers
UCB’s Portfolio 5 Unique and De-risked Growth Drivers ® First agent for anti-AChR+ & anti-MuSK+ First-in-class for Bone Builder Proprietary and Confidential Property of UCB First once-daily C5 inhibitor Unique and dual mode of action First and only IL-17A & IL-17F inhibitor1 1 Demonstrated in Psoria
Slide 7: UCB's Performance: Past Inflection Point and Started a Decade+ of Growth
UCB’s Performance Past Inflection Point and Started a Decade+ of Growth 2023 FINANCIAL and EXTRA-FINANCIAL 2023 MARKED BY 2024 MARKED BY 2023 financial guidance delivered >3.2 million patients using UCB medicines1, Strong growth of EVENITY®, FINTEPLA®, 40% of epilepsy treatments in US + EU (Japan 30
Slide 8: Focus on BIMZELX
02 Focus on BIMZELX® Proprietary and Confidential Property of UCB BIMZELX® offering potential for best in disease and best in class Emmanuel Caeymaex EVP Immunology & Head of U.S. UCB - FY results 2023, February 2024 8
Slide 9: BIMZELX ex-U.S.: Accelerated Launch driven by Patient Experience
BIMZELX® ex-U.S. Accelerated Launch driven by Patient Experience and the Launch of PsA & axSpA BIMZELX® Leading IL-17 performance in PSO (excl. BIMZELX® in Germany | PsA & axSpA U.S.) Launch Uptake vs. Analogues1 (anti-interleukins) in less than 2 years ≥35% Proprietary and Confidential Property of
Slide 10: BIMZELX in U.S.: Strong Start
BIMZELX® in U.S. Strong start: Strategic Investment Behind the Launch BIMZELX® in U.S. | Uptake in PSO Psoriasis U.S. Market Outlook3 Psoriasis Launch Uptake vs. Analogues1 BIMZELX® expected class leader3 +23% $21.7bn Proprietary and Confidential Property of UCB Weekly TRx $17.6bn W1 W2 W3 W4 W5 W6
Slide 11: Our Innovation
03 Our Innovation Proprietary and Confidential Property of UCB Promising pipeline complementing the existing portfolio of growth drivers Iris Loew-Friedrich CMO UCB - FY results 2023, February 2024 11
Slide 12: Cutting-edge Innovation Delivering Unprecedented Tally of Approvals
Cutting-edge Innovation Delivering Unprecedent Tally of Approvals Approvals and Submissions 14 approvals H1 2023 H2 2023 H1 2024 since January 2023 FINTEPLA® BIMZELX® ZILBRYSQ® BIMZELX® RYSTIGGO® LGS PsA gMG PsA gMG Proprietary and Confidential Property of UCB EU EU Japan Japan EU RYSTIGGO® BIMZELX®
Slide 13: Cutting-edge Innovation Delivering Industry-leading Pipeline
Cutting-edge Innovation Delivering Industry-leading Pipeline 8 new solutions PHASE 1 PHASE 2 PHASE 3 TOPLINE RESULTS 10 patient populations rozanolixizumab (FcRn inhibitor) 12 clinical programs MOG-antibody disease H2 2024 11 news flows in 2024 Ph-2a H1 2024 Autoimmune encephalitis Severe fibromya
Slide 14: Our Performance
04 Our Performance Proprietary and Confidential Property of UCB Strong financial management through growth inflection Sandrine Dufour CFO UCB - FY results 2023, February 2024 14
Slide 15: Solid Foundation & Growth Drivers
Solid Foundation & Growth Drivers Growth Past Inflection Point Growth H2 vs. H1* FY23 - M ACT CER Seizures associated with rare epileptic syndromes - Dravet Syndrome (DS) and FINTEPLA® +22% € 226 +94% +99% Growth Lennox-Gastaut Syndrome (LGS), acquired in March 2022, ongoing launches Drivers Approve
Slide 16: 2023 Performance Highlights
2023 Performance Highlights Efficient Performance and Cost Management 2023 Actual CER Net Sales € 4 867M (-5%; -6% CER) Revenue strong growth of BRIVIACT®, FINTEPLA® and BIMZELX®, more than offset by the loss of exclusivity € 5 252 M -5% -6% of 2 products, stable performance of CIMZIA® Well in-line
Slide 17: Delivery on Social and Environmental Impact
Delivery on Social and Environmental Impact As per UCB Sustainable Performance Goals Key Performance Indicator 2023 ∆ 2022 Number of medicines in 10 1 clinical development* Access Coverage Performance 68% 24% Index** Value for Proprietary and Confidential Property of UCB Patient Time to Access Index
Slide 18: Financial Guidance 2024
Strategically Investing Behind Launches and Securing Sustainable Growth Financial Guidance 2024 2024 Guidance Revenue expected € 5.5 - 5.7 bn Proprietary and Confidential Property of UCB Growth drivers BIMZELX®, BRIVIACT®, FINTEPLA®, RYSTIGGO®, ZILBRYSQ®, EVENITY® Adjusted EBITDA / revenue margin ex
Slide 19: Financial Guidance 2025
Strategically Investing Behind Launches and Securing Sustainable Growth Financial Guidance 2025 2025 Guidance At least € 6bn top line 5 revenue growth drivers EVENITY®, FINTEPLA®, BIMZELX®, RYSTIGGO®, ZILBRYSQ® Proprietary and Confidential Property of UCB Low- to mid-thirties adj. EBITDA margin >€6b
Slide 20: Decade+ of Growth
05 Decade+ of Growth Proprietary and Confidential Property of UCB Solid foundation & differentiated innovation enabling a decade+ of growth Jean-Christophe Tellier CEO UCB - FY results 2023, February 2024 20
Slide 21: Our Building Blocks for a Decade+ of Growth
Our Building Blocks for a Decade+ of Growth Pioneering Deliver differentiated solutions with unique outcomes for patients Innovation Proprietary and Confidential Property of UCB Invest behind the launches Leveraging Excellence in execution Core Strengths Disciplined resource allocation Amplifying Ma
Slide 22: Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB